Guangzhou Yinno Pharmaceutical Group

Guangzhou Yinno Pharmaceutical Group is a clinical-stage biotechnology company headquartered in Guangzhou, China, dedicated to the development of next-generation T-cell receptor engineered T-cell (TCR-T) therapies. The company focuses on addressing unmet medical needs in solid tumors, utilizing its proprietary platform to identify and optimize TCRs targeting specific tumor antigens such as AFP and NY-ESO-1. Its lead candidate, YN-001, is a first-in-class TCR-T therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. Yinno Pharma's integrated approach spans from early-stage discovery to clinical development and GMP manufacturing. The company aims to transform the landscape of cancer immunotherapy through its innovative cell therapy pipeline. By leveraging high-affinity TCR discovery, the group seeks to overcome the immunosuppressive environment of solid malignancies.